Emcure Pharmaceuticals has raised a significant amount of funding through its anchor book, with notable global investors such as the Abu Dhabi Investment Authority, Goldman Sachs, and Morgan Stanley participating. The company has also secured investments from several mutual funds, insurance companies, and other institutional investors. This capital will allow Emcure to strengthen its position in the pharmaceutical industry and continue its growth and development.
Emcure Pharmaceuticals, a leading pharma company headquartered in Pune, has raised Rs 583 crore from prominent investors including HDFC Mutual Fund, ICICI Prudential MF, SBI MF, and Abu Dhabi Investment Authority, among others. The upcoming IPO, priced at Rs 960 to Rs 1,008 per share, is set to hit the market on July 3 and close on July 5. With a total offering of Rs 1,952 crore, including an offer for sale of Rs 1,152 crore and fresh equity shares worth Rs 800 crore, Emcure's market valuation is estimated at over Rs 19,000 crore. The raised capital will be used for debt repayments and general corporate expenses.
Emcure Pharmaceuticals, founded by Namita Thapar's father, is set to raise around Rs. 1,952 crore through its IPO. Thapar, the Executive Director, will sell a 3.5% stake in the company, potentially making Rs. 126 crore. With key therapeutic areas and a strong global presence, Emcure's debut on the market comes at an opportune time for India's pharma sector.